To this end, baseline expression values of the different blood biomarkers were compared between patients with HER2-non-amplified luminal-like BC who developed distant metastases within five years and patients who remained disease-free for at least seven years after initial diagnosis and primary treatment. This evidence concerns the gene ERBB2 and breast cancer.